8 Questions on Managing, Treating Lung Cancer

Article

Do you know incidence of lung cancer in the United States? How about which lymph node station is not evaluable with esophageal ultrasound-guided biopsy in newly diagnosed disease? Answer these questions and more.

Question 1:

Answer and Question 2 on Next Page »

The correct answer is C. Levels 5 and 6

Question 2:

Answer and Question 3 on Next Page »

The correct answer is D. Chemotherapy and radiation alone

Question 3:

Answer and Question 4 on Next Page »

The correct answer is B. Hypertrophic pulmonary osteoarthropathy

Question 4:

Answer and Question 5 on Next Page »

The correct answer is A. True

Question 5:

Answer and Question 6 on Next Page »

The correct answer is D. 224,390

Question 6:

Answer and Question 7 on Next Page »

The correct answer is B. 6

Question 7:

Answer and Question 8 on Next Page »

The correct answer is C. 10% to 15%

Question 8:

Answer on Next Page »

The correct answer is C. 158,080

 

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content
Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Radioligand Therapy Combo Boosts rPFS in PSMA+ Metastatic HSPC

Chris Ryan
October 19th 2025
Article

Findings from the PSMAddition trial support the benefit of the early addition of lutetium Lu 177 vipivotide tetraxetan in metastatic HSPC.

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Sirexatamab Combo Shows Efficacy in DKK1-High Metastatic CRC Subgroups

Tony Berberabe, MPH
October 19th 2025
Article

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.

Enfortumab Vedotin/Pembrolizumab Display Frontline Efficacy in PD-L1+ HNSCC

Jax DiEugenio
October 19th 2025
Article

The investigator-evaluated ORR was 39.0% among those treated for recurrent/metastatic HNSCC, and the CR and PR rates were 9.8% and 29.3%, respectively.

Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.

Tislelizumab Regimen Exhibits Improved Survival in Locally Advanced ESCC

Caroline Seymour
October 19th 2025
Article

Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.